EN
instrument_fundamentals
| date | Close | change | Change (%) | instr__open | High | Low |
|---|
News
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC (AZN) | Morningstar
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC
Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million | Morningstar
Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock Up
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca | The Manila Times
AstraZeneca withdraws EU application for experimental lung cancer drug | Company News - Business Standard
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU | Morningstar
AstraZeneca And Daiichi Sankyo Withdraw EU Marketing Application For Datopotamab Deruxtecan | Markets Insider
Astra, Daiichi Withdraw EU Application for Lung Cancer Drug
AstraZeneca asthma drug more effective during attack than steroids, study finds
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn By Investing.com
AstraZeneca Loses Bid to Block Mississippi Drug Discount Law
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN | Morningstar
Why Is AstraZeneca PLC (AZN) Among the Best European Dividend Stocks To Buy Now?
10 Best European Dividend Stocks To Buy
AstraZeneca's Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer By Investing.com
Astra’s Tagrisso Gets EU Nod for Another Form of Lung Cancer
AstraZeneca's Tagrisso Gets EU Approval For Unresectable EGFR-mutated Lung Cancer
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC - December 23, 2024 - Zacks.com
M&T Bank Corp Has $19.56 Million Stake in AstraZeneca PLC (NASDAQ:AZN)
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
Why Astrazeneca (AZN) Outpaced the Stock Market Today - December 20, 2024 - Zacks.com
Congestive Heart Failure Drugs Market 2030: The Future of Injectable Formulations – Express Press Release Distribution
Beijing woos AstraZeneca for investment while probe continues
AstraZeneca Faces Major Investigation in China
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN By Investing.com
AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights | Morningstar
AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights | Valuespectrum.com
Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT
AstraZeneca's Alexion Inks Deal With Pan-Canadian Pharmaceutical Alliance | Markets Insider
AstraZeneca PLC (NASDAQ:AZN) Short Interest Down 8.3% in November
Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN | Morningstar
World Investment Advisors LLC Has $644,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)
Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN | Morningstar
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman | Morningstar
AstraZeneca's SWOT analysis: oncology giant's stock poised for growth By Investing.com
Drug company: We won’t charge more for ‘green’ inhalers
Short Interest in AstraZeneca PLC (NASDAQ:AZN) Drops By 8.3%
AstraZeneca announces board refresh with new directors By Investing.com
AstraZeneca Strengthens Board with New Non-Executive Director Appointments
AstraZeneca names new non-executive directors By Investing.com
Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year By Investing.com
AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Update
SpringWorks Therapeutics' SWOT analysis: stock potential amid clinical progress By Investing.com
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by State Street Corp
AstraZeneca PLC ADRhedged (AZNH) To Go Ex-Dividend on December 16th
Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer
Peapack Gladstone Financial Corp Acquires 23,159 Shares of AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Peapack Gladstone Financial Corp
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Verition Fund Management LLC
FDA Revokes EUA for Evusheld (tixagevimab co-packaged with cilgavimab) for the Treatment of COVID-19
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth | Morningstar
Franklin Resources Inc. Acquires 1,522,715 Shares of AstraZeneca PLC (NASDAQ:AZN)
Kyverna Therapeutics Strengthens Leadership Team By Investing.com
Wilmington Savings Fund Society FSB Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ:AZN) Holdings Lowered by Vestcor Inc
New Investigation Casts Doubt on Landmark Ticagrelor Trial | MDedge
Case: Discrimination/Pay Equity (D. Md.)
Virtu Financial LLC Takes $4.82 Million Position in AstraZeneca PLC (NASDAQ:AZN)
Advisory Resource Group Takes $946,000 Position in AstraZeneca PLC (NASDAQ:AZN)
Tracer Biotechnologies partners with AstraZeneca on ctDNA tech By Investing.com
HUTCHMED: ORPATHYS And TAGRISSO Get Breakthrough Therapy Designation In China For NSCLC | Markets Insider
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy | Morningstar
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy | Valuespectrum.com
Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN) | Markets Insider
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial | Morningstar
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial | Morningstar
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by National Bank of Canada FI
AstraZeneca PLC (LON:AZN) Receives Average Rating of "Moderate Buy" from Analysts
AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China
Groupama Asset Managment Purchases 101,225 Shares of AstraZeneca PLC (NASDAQ:AZN)
MML Investors Services LLC Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Y Intercept Hong Kong Ltd
Spatial biology captures the effects of neoadjuvant chemo-immunotherapy in lung cancer
More Biologics May Be Breaking Through for COPD | MDedge
AstraZeneca Africa staff join ‘Week of Service, highlight commitment to community sustainability
In the clinic for December 10, 2024 | BioWorld
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC - December 10, 2024 - Zacks.com
FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag - December 9, 2024 - Zacks.com
In the clinic for Dec. 9, 2024 | BioWorld
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer By Investing.com
Centiva Capital LP Buys New Shares in AstraZeneca PLC (NASDAQ:AZN)
Wexford Capital LP Sells 7,859 Shares of AstraZeneca PLC (NASDAQ:AZN)
FDA Grants Priority Review to AstraZeneca’s Imfinzi for Muscle-Invasive Bladder Cancer
AstraZeneca's Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer By Investing.com
AstraZeneca's Imfinzi Gains FDA Approval for New LS-SCLC Treatment
AZN : TROPION Analysis Reveals Datopotamab Deruxtecan Efficacy In Advanced EGFR-Mutated Lung Cancer
Imfinzi shows promise in bladder cancer trial, seeks FDA approval By Investing.com
FDA Approves Durvalumab for Limited-Stage SCLC | MDedge
